Eswatini’s HIV Prevention Breakthrough Exposes Fragile U.S. Aid Priorities

In a landmark moment for African public health, Eswatini has become the first continent nation to receive lenacapavir, an innovative twice-yearly injection that promises near-total protection against HIV. Developed by Gilead Sciences and approved in the United States only months ago, this drug arrives as a beacon of hope for millions living with or at risk of HIV across sub-Saharan Africa.What Does This Mean for American Leadership and National Security?At first glance, this breakthrough seems like a win for global health. But beneath the surface lies a troubling reality: The rollout is part of PEPFAR, an initiative whose funding has...